ArticleAntimicrobial agents and chemotherapy2013
Limited activity of miltefosine in murine models of cryptococcal meningoencephalitis and disseminated cryptococcosis.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Article
- Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.Infection and drug resistance · 2024Review
- Article
- Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosisAntimicrobial agents and chemotherapy · 2023Article
- Phospholipase B Is Critical for Cryptococcus neoformans Survival in the Central Nervous System.mBio · 2023Article
- Palmitoylethanolamide shows limited efficacy in controlling cerebral cryptococcosisbioRxiv : the preprint server for biology · 2023Article
- Oral delivery of brain-targeted miltefosine-loaded alginate nanoparticles functionalized with polysorbate 80 for the treatment of cryptococcal meningitis.The Journal of antimicrobial chemotherapy · 2023Article
- Clinical and pathological characterization of Central Nervous System cryptococcosis in an experimental mouse model of stereotaxic intracerebral infection.PLoS neglected tropical diseases · 2023Article
- In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins ResistantJournal of fungi (Basel, Switzerland) · 2022Article
- Article
- New Approaches for Cryptococcosis Treatment.Microorganisms · 2020Review
- New Triazole NT-a9 Has Potent Antifungal Efficacy against Cryptococcus neoformansAntimicrobial agents and chemotherapy · 2020Article
- Article
- Efficacy of Azithromycin and Miltefosine in Experimental Systemic Pythiosis in Immunosuppressed Mice.Antimicrobial agents and chemotherapy · 2019Article
- Article
- The Fungal Cyp51 Inhibitor VT-1129 Is Efficacious in an Experimental Model of Cryptococcal Meningitis.Antimicrobial agents and chemotherapy · 2018Article
- Article
- The antifungal pipeline: a reality check.Nature reviews. Drug discovery · 2017Review
- Inositol Polyphosphate Kinases, Fungal Virulence and Drug Discovery.Journal of fungi (Basel, Switzerland) · 2016Review
- Isavuconazole Is Effective for the Treatment of Experimental Cryptococcal Meningitis.Antimicrobial agents and chemotherapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Miltefosine is an alkyl phosphocholine with good oral bioavailability and in vitro activity against Cryptococcus species that has gained interest as an additional agent for cryptococcal infections. Our objective was to further evaluate the in vivo efficacy of miltefosine in experimental in vivo models of cryptococcal meningoencephalitis and disseminated cryptococcosis. Mice were infected intracranially or intravenously with either C. neoformans USC1597 or H99. Miltefosine treatment (1.8 to 45 mg/kg of body weight orally once daily) began at either 1 h or 1 day postinoculation. Fluconazole (10 mg/kg orally twice daily) or amphotericin B deoxycholate (3 mg/kg intraperitoneally once daily) served as positive controls. In our standard models, miltefosine did not result in significant improvements in survival or reductions in fungal burden against either C. neoformans isolate. There was a trend toward improved survival with miltefosine at 7.2 mg/kg against disseminated cryptococcosis with the H99 strain but only at a low infecting inoculum. In contrast, both fluconazole and amphotericin B significantly improved survival in mice with cryptococcal meningoencephalitis and disseminated cryptococcosis due to USC1597. Amphotericin B also improved survival against both cryptococcal infections caused by H99. Combination therapy with miltefosine demonstrated neither synergy nor antagonism in both models. These results demonstrate limited efficacy of miltefosine and suggest caution with the potential use of this agent for the treatment of C. neoformans infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.